Pacira Pharmaceuticals, Inc. Release: New Publication Suggests Higher Opioid Use in the Postsurgical Setting May be Linked to Extended Hospital Stay and Increased Cost of Care
12/18/2012 9:23:33 AM
PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that the full findings from the regional health system analysis conducted by Barnabas Health to quantify the relationship between opioid use, total hospital charges and patient length of stay (LOS) were published in Hospital Pharmacy. This study demonstrated that in addition to increased hospital charges, patients undergoing total abdominal hysterectomy (TAH) with an unusually long LOS (five days or more) also had a higher incidence of opioid-related adverse events (ORAEs) compared to the control group of patients with a more typical LOS (less than five days). Preliminary findings from this retrospective analysis were discussed in a poster presentation given at the American Society of Health-System Pharmacists meeting in December 2011.